SCHEMBL23218126

SCHEMBL23218126

CCc1ccc(CC(=O)O)c(OCc2coc3ccc(-c4cccc(CN)c4F)cc23)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 8/20 0.42
TP53 P04637 3/20 0.40
CD274 Q9NZQ7 1/20 0.40
F11 P03951 2/20 0.39
KLKB1 P03952 2/20 0.39
PLG P00747 1/20 0.39
PLAU P00749 1/20 0.39
F7 P08709 1/20 0.39
TPSB2 P20231 1/20 0.39
PTGER1 P34995 1/20 0.38
PTGER4 P35408 1/20 0.38
PTGER3 P43115 1/20 0.38
PTGER2 P43116 1/20 0.38
FFAR1 O14842 1/20 0.38
MAPT P10636 2/20 0.36
THRB P10828 1/20 0.36
PPARD Q03181 1/20 0.35
LTB4R Q15722 1/20 0.35
LTB4R2 Q9NPC1 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29592059 1.00 CFD (0.42) CFDTP53CD274F11KLKB1
SCHEMBL23218397 0.91 CFD (0.38) CFDTP53CD274MAPTTHRB
SCHEMBL29852372 0.91 CFD (0.38) CFDTP53CD274MAPTTHRB
SCHEMBL29592710 0.89 CFD (0.49) CFDCD274F11KLKB1PLG
SCHEMBL23218539 0.89 CFD (0.49) CFDCD274F11KLKB1PLG
SCHEMBL23218388 0.88 CD274 (0.43) CFDCD274F11KLKB1PLG
SCHEMBL29591230 0.88 CD274 (0.43) CFDCD274F11KLKB1PLG
SCHEMBL23218197 0.86 CFD (0.53) CFDTP53F11KLKB1PLG
SCHEMBL29592561 0.86 CFD (0.53) CFDTP53F11KLKB1PLG
SCHEMBL23218864 0.84 CFD (0.43) CFDCD274F11KLKB1PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885TP53 3891/4885CD274 2774/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885TP53 3580/4885CD274 4001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.